Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia

Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of anemia in patients with chronic kidney disease. However, EPO-resistance is an important contributor to the increased risk of adverse effects. We previously showed that EPO treatment could induce precurs...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Xiaoqing, Krzyzanski, Wojciech, Liu, Dongyang, Wong, Raymond S. M., Yan, Xiaoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962863/
https://www.ncbi.nlm.nih.gov/pubmed/36839666
http://dx.doi.org/10.3390/pharmaceutics15020344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962863/
https://www.ncbi.nlm.nih.gov/pubmed/36839666
http://dx.doi.org/10.3390/pharmaceutics15020344

Ejemplares similares